Home › Calculator › GNMSF Dividend Calculator 2026
GNMSF Dividend Calculator 2026
No dividendHealthcareGenmab A/S · OTC
Price: $447.55 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
Calculator settings
GNMSF is not a dividend-focused stock
GNMSF pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
GNMSF Dividend Yield
Genmab A/S (GNMSF) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When GNMSF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
About Genmab A/S (GNMSF) — Dividend Analysis 2026
Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases. The company markets several key products, including DARZALEX (daratumumab) for multiple myeloma, teprotumumab for thyroid eye disease, ofatumumab to address chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric, esophageal, and non-small cell lung cancers. Their extensive pipeline includes daratumumab, also being explored for non-MM blood cancers and AL amyloidosis, along with GEN1047, tisotumab vedotin for cervical, ovarian, and other solid cancers, and specialized DuoBody and HexaBody platforms targeting various solid tumors and hematological malignancies, such as Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and CLL. Genmab further maintains approximately 20 active pre-clinical programs and a diverse array of compounds in Phase 2 development, investigating treatments for conditions like vaso-occlusive crises (Teclistamab), Hodgkin lymphoma and solid tumors (Camidanlumab tesirine), multiple myeloma (JNJ-64007957 and JNJ-64407564), celiac disease (PRV-015), hemophilia A (Mim8), and multiple system atrophy (Lu AF82422). The company engages in significant strategic collaborations, notably with Seagen Inc. for the co-development of tisotumab vedotin, CureVac AG for mRNA-based antibody products, and AbbVie for Epcoritamab, alongside other partnerships with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
GNMSF Dividend & DRIP — Frequently Asked Questions
Does GNMSF pay a dividend?
No. Genmab A/S (GNMSF) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
How can I get dividend income instead of GNMSF?
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
Does GNMSF have a DRIP (dividend reinvestment plan)?
A DRIP reinvests dividends into new shares. GNMSF has no regular dividend in our data, so there is nothing to reinvest.
Stocks similar to GNMSF
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full GNMSF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GNMSF position with:
🌍 GNMSF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold GNMSF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 GNMSF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 GNMSF Dividend Payment Schedule
GNMSF pays quarterly — 4 times per year. Ex-div: —.
📊 GNMSF vs Healthcare Benchmarks
How GNMSF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GNMSF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ GNMSF Insider Activity
No recent SEC filings reported in the last 90 days.Peer Group
Similar companies in the same sectorCompare GNMSF with peers: GNMSF vs CMXHF · GNMSF vs CSLLY · GNMSF vs GMAB
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GNMSF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Genmab A/S (GNMSF) is currently trading at $447.55, trading near its 52-week high. It does not currently pay a regular dividend.
Does GNMSF Pay a Dividend? Genmab A/S Dividend Status
Genmab A/S (GNMSF) is a healthcare stock trading at $447.55. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
- Without a dividend, returns depend entirely on the share price.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest GNMSF News
LiveProjected your GNMSF DRIP returns?
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.